Novel marginal zone lymphoma models of resistance to the dual inhibition of PI3K and BCL2

被引：0
|
作者：
Arribas, Alberto J.
Cascione, Luciano
Cannas, Eleonora
Bellerjeau, Helen
Fuzio, Federica
Noguera, Aleix
Rinaldi, Andrea
Esteller, Manel
Zucca, Emanuele
Alimonti, Andrea
Rossi, Davide
Stathis, Anastasios
Bertoni, Francesco
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-534
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
534
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Non-Coding RNAs Regulate Novel Signaling Pathways in AL Amyloidosis That Are Targetable By BCL2, PI3K and MEK Inhibitors
    Zvida, Tal
    Muchtar, Eli
    Salmon-Divon, Mali
    Dispenzieri, Angela
    Fishov, Hila
    Schneider, Claudio
    Bender, Benjamin
    Duek, Adrian
    Leiba, Merav
    Shpilberg, Ofer
    Hershkovitz-Rokah, Oshrat
    BLOOD, 2022, 140 : 7074 - 7075
  • [32] PI3K and BTK Inhibition Induces the Upregulation of CD19 and Increases Sensitivity to CAR T Cells in a Model of Marginal Zone Lymphoma (MZL)
    Wang, Sisi
    Arribas, Alberto J.
    Tarantelli, Chiara
    Pradier, Amandine
    Di Bergamo, Lodovico Terzi
    Zucca, Emanuele
    Rossi, Davide
    Simonetta, Federico
    Bertoni, Francesco
    BLOOD, 2022, 140 : 4554 - 4555
  • [33] Dual inhibition of PI3K and Erk1/2 shows synergy and efficacy in human tumor cells, either by using drug combinations or novel dual PI3K/Erk inhibitors
    Seipelt, Irene
    Gerlach, Matthias
    Blumenstein, Lars
    Mueller, Gilbert
    Guenther, Eckhard
    Engel, Juergen
    Teifel, Michael
    CANCER RESEARCH, 2012, 72
  • [34] PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells
    Zhu, Shudong
    Cohen, Matthew B.
    Bjorge, Jeffrey D.
    Mier, James W.
    Cho, Daniel C.
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2013, 17 (03) : 377 - 385
  • [35] Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
    Maria Serova
    Armand de Gramont
    Annemilaï Tijeras-Raballand
    Célia Dos Santos
    Maria Eugenia Riveiro
    Khemaies Slimane
    Sandrine Faivre
    Eric Raymond
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1297 - 1307
  • [36] Dual Inhibition of MCL1 and BCL2 in Lymphoma Using Tumor Targeted Nanoparticles
    Bala, Neeta Bala
    Manzari, Mandana Taghizadeh
    Ferreira, Mariana Da Silva
    Asgari, Zahra
    Hagen, Connor
    Seshan, Venkatraman
    de Stanchina, Elisa
    Manova-Todorova, Katia
    Heller, Daniel
    Younes, Anas
    BLOOD, 2019, 134
  • [37] Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
    Serova, Maria
    de Gramont, Armand
    Tijeras-Raballand, Annemilai
    Dos Santos, Celia
    Riveiro, Maria Eugenia
    Slimane, Khemaies
    Faivre, Sandrine
    Raymond, Eric
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1297 - 1307
  • [38] PI3K inhibition to overcome endocrine resistance in breast cancer
    Keegan, Niamh M.
    Gleeson, Jack P.
    Hennessy, Bryan T.
    Morris, Patrick G.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (01) : 1 - 15
  • [39] Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
    Tarantelli, Chiara
    Lupia, Antonio
    Stathis, Anastasios
    Bertoni, Francesco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (03)
  • [40] Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors
    Chanal, Marie
    Chevallier, Pascale
    Raverot, Veronique
    Fonteneau, Guillaume
    Lucia, Kristin
    Garcia, Jose Luis Monteserin
    Rachwan, Alexa
    Jouanneau, Emmanuel
    Trouillas, Jacqueline
    Honnorat, Jerome
    Auger, Carole
    Theodoropoulou, Marily
    Raverot, Gerald
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (06) : 1261 - 1270
12345